scholarly journals Glucose Lowering Effect of Brown Pigmented Rice (oryza sativa l) in Diet-Induced Hyperglycemic Sprague Dawley Rats

2021 ◽  
Vol 11 (6) ◽  
pp. 2153
Author(s):  
Heni Purwaningsih ◽  
Wilma A. Hurtada ◽  
Aimee Sheree A. Barrion ◽  
Marites G. Yee ◽  
Josefina T. Dizon ◽  
...  
Keyword(s):  
Oryza Sativa ◽  
Oryza Sativa L ◽  
Sprague Dawley ◽  
Glucose Lowering ◽  
Pigmented Rice ◽  
Lowering Effect ◽  
Sprague Dawley Rats ◽  
Glucose Lowering Effect

Postprandial glucose-lowering effect of cagaita (Eugenia dysenterica DC) fruit juice in dysglycemic subjects with metabolic syndrome: An exploratory study

2021 ◽  
Vol 142 ◽  
pp. 110209
Author(s):  
Renata Luise de Araujo ◽  
Francisco A. Tomás-Barberán ◽  
Rosa Ferreira dos Santos ◽  
J. Alberto Martinez-Blazquez ◽  
Maria Inés Genovese
Keyword(s):  
Metabolic Syndrome ◽  
Exploratory Study ◽  
Fruit Juice ◽  
Postprandial Glucose ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Eugenia Dysenterica

P356 GLUCOSE-LOWERING EFFECT OF APPLE POLYPHENOLS IN INSULIN RESISTANT OBESE ZUCKER RATS

2008 ◽  
Vol 3 ◽  
pp. 180
Author(s):  
M. Manzano ◽  
M.L. Jimenez ◽  
R. Rueda ◽  
J.M. Lopez-Pedrosa
Keyword(s):  
Zucker Rats ◽  
Glucose Lowering ◽  
Insulin Resistant ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Obese Zucker Rats

Activation of the gut calcium-sensing receptor by peptide agonists reduces rapid elevation of plasma glucose in response to oral glucose load in rats

2014 ◽  
Vol 306 (12) ◽  
pp. G1099-G1107 ◽  
Author(s):  
Maya Muramatsu ◽  
Tohru Hira ◽  
Arimi Mitsunaga ◽  
Eri Sato ◽  
Shingo Nakajima ◽  
...  
Keyword(s):  
Gastric Emptying ◽  
Glucose Tolerance ◽  
Oral Glucose ◽  
Calcium Sensing Receptor ◽  
Gastric Emptying Rate ◽  
Glucose Lowering ◽  
Conscious Rats ◽  
Lowering Effect ◽  
Calcium Sensing ◽  
Glucose Lowering Effect

The calcium-sensing receptor (CaSR) is expressed in various tissues, including the gastrointestinal tract. To investigate the role of gut CaSR on glycemic control, we examined whether single oral administration of CaSR agonist peptides affected the glycemic response in rats. Glucose tolerance tests were performed under oral or duodenal administration of various CaSR agonist peptides (γGlu-Cys, protamine, and poly-d-lysine hydrobromide) in conscious rats. Involvement of CaSR was determined by using a CaSR antagonist. Signaling pathways underlying CaSR agonist-modified glycemia were investigated using gut hormone receptor antagonists. The gastric emptying rate after the administration of CaSR agonist peptides was measured by the phenol red recovery method. Oral and duodenal administration of CaSR agonist peptides attenuated glycemic responses under the oral glucose tolerance test, but the administration of casein did not. The promotive effect on glucose tolerance was weakened by luminal pretreatment with a CaSR antagonist. Treatment with a 5-HT3 receptor antagonist partially diminished the glucose-lowering effect of peptides. Furthermore, the gastric emptying rate was decreased by duodenal administration of CaSR agonist peptides. These results demonstrate that activation of the gut CaSR by peptide agonists promotes glucose tolerance in conscious rats. 5-HT3 receptor and the delayed gastric emptying rate appear to be involved in the glucose-lowering effect of CaSR agonist peptides. Thus, activation of gut CaSR by dietary peptides reduces glycemic responses so that gut CaSR may be a potential target for the improvement of postprandial glycemia.

scholarly journals Glucose lowering effect of Zornia gibbosa Span extracts in diabetic rats

2018 ◽  
Author(s):  
Mallikarjuna Rao Talluri ◽  
Rajananda Swamy Tadi ◽  
Ganga Rao Battu ◽  
Zubair Mohammad
Keyword(s):  
Diabetic Rats ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect

scholarly journals Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-blind, Crossover Study in Men With Type 1 Diabetes

2020 ◽  
Author(s):  
Eva Svehlikova ◽  
Ines Mursic ◽  
Thomas Augustin ◽  
Christoph Magnes ◽  
David Gerring ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Crossover Study ◽  
Insulin Aspart ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Onset Of Action ◽  
Double Blind ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect

OBJECTIVE <p>To investigate the pharmacokinetic and pharmacodynamic properties, and safety of a novel formulation of insulin aspart (AT247) versus currently marketed insulin aspart formulations (IAsp and faster IAsp).</p> <p> </p> <p>RESEARCH DESIGN AND METHODS</p> <p>This single-center, randomized, double-blind, three-period, crossover study was conducted in 19 men with type 1 diabetes, receiving single dosing of trial products (0.3 U/kg) in a random order on three visits. Pharmacokinetics and pharmacodynamics were assessed during a euglycemic clamp lasting up to 8 hours. </p> <p> </p> <p>RESULTS</p> <p>Onset of insulin appearance was earlier for AT247 compared with IAsp (−12 minutes [95% CI −14;−8] p=0.0004) and faster IAsp (−2 minutes [−5;−2] p=0.0003). Onset of action was accelerated compared with IAsp (−23 minutes [−37;−15] p=0.0004) and faster IAsp (−9 minutes [−11;−3] p=0.0006). Within the first 60 minutes, a higher exposure was observed for AT247 compared with IAsp (AUC<sub>Asp,0-60min</sub>: treatment ratio vs IAsp 2.3 [1.9;2.9]; vs faster IAsp 1.5 [1.3;1.8]), which was underpinned by a greater early glucose-lowering effect (AUC<sub>GIR,0-60min</sub>: treatment ratio vs IAsp 2.8 [2.0;5.5]; vs faster IAsp 1.7 [1.3;2.3]). Furthermore, an earlier offset of exposure was observed for AT247 compared with IAsp (−32 minutes [−58;−15] p=0.0015) and faster IAsp (−27 minutes [−85;−15] p=0.0017), while duration of glucose-lowering effect, measured by t<sub>Late50%GIRmax</sub>, did not differ significantly.</p> <p> </p> <p>CONCLUSIONS</p> <p>AT247 exhibited an earlier insulin appearance, exposure and offset, with corresponding enhanced early glucose-lowering effect compared with IAsp and faster IAsp. It therefore represents a promising candidate in the pursuit for second generation prandial insulin analogs to improve postprandial glycemic control.</p>

Glucose-lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

2012 ◽  
Vol 36 (5) ◽  
pp. S46-S47
Author(s):  
Leszek Nosek ◽  
Hans-Veit Coester ◽  
Henrik F. Thomsen ◽  
Carsten Roepstorff ◽  
Hanne L. Haahr ◽  
...  
Keyword(s):  
Subcutaneous Injection ◽  
Insulin Degludec ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Injection Region
Sign in / Sign up

Export Citation Format

Share Document